American Family Children's Hospital

The UW Carbone Cancer Center (UWCCC) Drug Development Core (DDC) supports world-class biomedical research by facilitating cancer-related pre-clinical drug discovery through the integration of high throughput screening, medicinal chemistry and pharmacology. These services are provided through the coordinated activities of the Small Molecule Screening Facility, the Cancer Pharmacology Laboratory and the Medicinal Chemistry Center.


The DDC Small Molecule Screening provides libraries of more than 400,000 compounds, robotic liquid handling and plate readers for high throughput screening of cell-based and biochemical assays in 96 to 1536-well plate formats. Computational resources and expertise are provided for in silico screens of millions of chemicals and for molecular modeling. Other specialized equipment includes a Seahorse Bioanalyzer for evaluation of cellular metabolism in 96-well format.


The DDC Medicinal Chemistry provides synthesis of small molecules that have been identified as bioactive, development of lead and probe molecules for target identification, hit-to-lead optimization to improve drug-like properties, construction of libraries of small molecules, and large-scale preparative synthesis to support animal model studies. Evaluation of in vitro and in vivo pharmacology is provided through in-house assays and contracts maintained with external contract research organizations.


The DDC Cancer Pharmacology Lab supports clinical trials conducted at UWCCC by providing analytical chemistry expertise needed to evaluate the pharmacokinetic and pharmacodynamic properties of study drugs. Acquisition, storage and shipping of patient samples are provided to support the clinical trial enterprise. DDC Cancer Pharmacology staff are tightly coordinated with the clinical trial enterprise at UWCCC including participation in the Cancer Therapy Discovery and Development (CTD2) group and the Disease Oriented Teams. The Cancer Pharmacology Core also provides analytical chemistry services for preclinical studies using HPLC or LC-MS to quantify small molecule drugs in user-provided biological samples including blood, urine or tissue. 


Any published research which received funding from the UWCCC Cancer Center Support Grant (CCSG), including the use of UWCCC Shared Resources to generate or analyze data or conduct clinical trials, must reference the UWCCC.


See Acknowledging UWCCC in Publications, Posters and Presentations 



Faculty Leaders

Ronald Burnette

Michael Hoffmann

Weiping Tang

Facility Managers

DDC Small Molecule Screening
Gene Ananiev

DDC Medicinal Chemistry
John Feltenberger

DDC Cancer Pharmacology
Joan Rettig

Lab Contact

Hours: 9am-5pm M-F